

Appendix 4C





ASX Release


Appendix 4C - Q4 2021 Quarterly Cash Flow Report

13 January 2022 – Sydney, Australia – Oneview Healthcare PLC ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 December 2021 (Q4 FY21).

Financial Highlights

The Company had a net operating cash inflow for the first time in its history. Net operating cash inflows totaled $\in 1.3m$. This incorporates the following:

Record receipts from customers of €5.46m (A\$8.6m), up 281% on the prior quarter and up 101% vs the previous corresponding period. This included €0.78m (A\$1.2m) of receipts which had been forecast for receipt in Q3 but were delayed and subsequently received in the first two weeks of Q4 2021, together with large payments from customers in respect of hardware sales and services. The final payments to suppliers in respect of these hardware sales were made in Q3. However, shipping delays due to Covid 19 resulted in delivery in Q4, at which point, customers paid upon delivery.



• The average quarterly cash outflow for 2021 was €981k which compares favorably to the average cash outflow for 2020 of €2,077k – an improvement of 53%.

Directors M Kaminski (Chairman) | N Asaria | L Berkowitz | J Fitter | J Rooney



- Payments for staff costs in the quarter were €2.4m (A\$3.8m), up 5% on the prior quarter driven by a small increase in headcount and commission payments to sales staff. Staff costs are up 16% vs previous corresponding period as the Company seeks to leverage its first mover advantage with Cloud.
- Administration and corporate costs of €0.8m (A\$1.3m) were in line with the previous quarter.
- The Company raised a total of A\$20m (€12.7m), excluding issue costs, from a timely and wellsupported share placement in the quarter to new and existing institutional and high net worth shareholders.
- The Company's cash balances as at 31 December 2021 were €15.2m (A\$24m), +123% vs 31 December 2020.

Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees totalling €102,000.

Operational Highlights

- On 20 October, Kingman Regional Medical Center in Kingman, Arizona signed a 5-year contract for our Cloud based Care Experience Platform (CXP). This was the first deal registered by Oneview under the Microsoft "co-sell" program. This new contract will bring Oneview's CXP Cloud Enterprise to the 235-bed multi-campus healthcare system in northwest Arizona. Hardware delivery to site has commenced and the project is expected to go live in by mid-2022.
- The Northern Health Cloud Start implementation was completed in 159 beds in Melbourne, Australia in Q4 2021. In addition, Oneview deployed Northern Health's existing TeleHealth solution across all 159 tablets to facilitate video consultations between patients and their care teams. The web-based TeleHealth service was configured and deployed within 3 business days, which is testament to the faster deployment times possible with Cloud. It has been invaluable in dealing with the surge in Covid-19 related admissions.
- The first batch of 1,719 Social Mobile GMS-certified healthcare-grade 22" AIO Android devices and 749 WeTek Hybrid (Coax & IPTV) Android Set-Top Boxes were delivered to customers during the quarter.
- Contract extensions were signed during the quarter with University of California San Francisco and the University of Iowa Children's Hospital.
- In December, the Company successfully passed the third penetration test of the year for our cloud hosted software, conducted by an independent cybersecurity consultancy.
- Following the unsuccessful mediation process in Q3 in relation to Oneview's claim for breach of the Collaboration Agreement between Oneview and Regis Aged Care Pty Ltd (a wholly owned subsidiary of Regis Healthcare Limited), Oneview continues its preparation for relisting of the proceedings with the Court.

Directors M Kaminski (Chairman) | N Asaria | L Berkowitz | J Fitter | J Rooney



CEO Outlook

The recent surge in Covid cases globally has clearly had a detrimental effect on sentiment and particularly hospital staffing but to-date has had no material impact on the Company's outlook for 2022. We have maintained a high level of engagement with both prospective customers and existing customers for expansion of the Oneview platform across more beds and customers transitioning to Cloud Enterprise.

Our access to healthcare customers' locations for sales and implementation activities remains limited in some cases due to the ongoing pandemic. The sales cycle and implementation timeline for broader strategic deals has been elongated as hospitals have been primarily focused on the operational impacts of the pandemic. Despite this, we are seeing appreciation of our value proposition, as an open scalable real-time technology platform at the bedside will assist our customers to cater to the rapidly changing hybrid models of care.

Based on the solid and growing pipeline of business we expect to place fresh OEM hardware orders with suppliers in the coming weeks to ensure we can meet anticipated demand in 2022.

ESG

At the start of this year, the Company committed to a Company-wide initiative around Environmental, Social and Governance and is pleased to report continued progress, as measured against the World Economic Forum universal ESG framework. Details can be found <u>HERE</u> on our website and will continue to be reported on a quarterly basis.

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital Care Experience Platform at the point of care, Oneview helps providers to measure and improve experience, optimize patient flow, deliver virtual care and enable patients and families with dedicated touch and TV devices. Oneview has partnered with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in 63 hospitals.

Enquiries: James Fitter, CEO Helena D'Arcy, Interim CFO Website : www.oneviewhealthcare.com

Directors M Kaminski (Chairman) | N Asaria | L Berkowitz | J Fitter | J Rooney



Appendix 4C

Quarterly cashflow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

31st December 2021

Consolidated statement of cash flows		Current quarter €'000	Year to date (12 months) €'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	5,458	11,688
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(1,580)	(4,579)
	(c) advertising and marketing	(118)	(419)
	(d) leased assets	-	-
	(e) staff costs	(2,377)	(8,989)
	(f) administration and corporate costs	(809)	(3,124)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	(3)	(56)
1.7	Government grants and tax incentives	-	1,251
1.8	Other – director's retirement payments	-	(177)
	Other – working capital movements	731	483
1.9	Net cash from / (used in) operating activities	1,302	(3,922)



2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(3)	(78)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(3)	(78)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	12,714	13,359
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	16	18
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(501)	(872)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(354)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	12,229	12,151



4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,542	6,804
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,302	(3,922)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	(78)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	12,229	12,151
4.5	Effect of movement in exchange rates on cash held	106	221
4.6	Cash and cash equivalents at end of period	15,176	15,176

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	15,176	1,542
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	15,176	1,542

6.	Payments to related parties of the entity and their associates (directors)	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1 (payments to directors)	102
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments



7. Financing facilities

Note: the term "facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.

- 7.1 Loan facilities
- 7.2 Credit standby arrangements
- 7.3 Other (please specify)
- 7.4 Total financing facilities

Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
-	-
-	-
-	-
-	-

7.5 Unused financing facilities available at quarter end

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	Estimated cash available for future operating activities	€'000
8.1	Net cash from / (used in) operating activities (Item 1.9)	1,302
8.2	Cash and cash equivalents at quarter end (Item 4.6)	15,176
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	15,176
8.5	Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	N/A

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:



2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 13 January 2022

Authorised by: **BY THE BOARD** (Name of body or officer authorising release – see note 4)

Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee e.g., Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance *Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.